Novo shares jump 6% as Wegovy pill sales impress, drugmaker hikes outlook
Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates…
AI stocks sell off as investors question AI spending returns
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., Oct.…
Eli Lilly (LLY) earnings Q3 2026
Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales…
Cramer: I asked tech insiders what to buy. They said Eli Lilly
Jim Cramer said Monday that even tech-focused people think the world of Eli Lilly stock, with one predicting…
Novo’s Wegovy pill improves weight loss after switch from injections
People who switched from obesity injections to Novo‘s new Wegovy pill continued to lose weight after three months,…
Lilly is ramping up future manufacturing for Foundayo obesity pill
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking…
Novo Nordisk rebrands to ‘Novo’ under CEO Mike Doustdar
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in…
This medical device stock looks like a gift for patient investors
Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes…
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
Wall Street analysts just called this healthcare stock a buy — here’s our take
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET.…
Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its…
We’re lifting our price target on Cardinal Health after issuing rosy profit guidance
Cardinal Health on Tuesday showed why the healthcare distributor belongs in our portfolio, delivering robust full-year earnings guidance…